Apollon Wealth Management LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Apollon Wealth Management LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.0% during the third quarter, HoldingsChannel reports. The fund owned 1,592 shares of the biopharmaceutical company’s stock after selling 83 shares during the quarter. Apollon Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,674,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. Sachetta LLC boosted its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the period. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $26,000. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth approximately $28,000. Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth approximately $33,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $33,000. 83.31% of the stock is currently owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.48% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of analyst reports. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Oppenheimer lowered their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Evercore ISI reduced their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,097.14.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $782.51 on Friday. The firm’s fifty day simple moving average is $1,000.06 and its two-hundred day simple moving average is $1,035.67. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market cap of $85.99 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 3.10 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52-week low of $780.95 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.